Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="179619"/>
<meta>
<versionId value="4"/>
<lastUpdated value="2023-12-06T00:11:33.141Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 179619</b></p><a name="179619"> </a><a name="hc179619"> </a><a name="179619-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 4; Last updated: 2023-12-06 00:11:33+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-systematic-review-eligibility-criteria.html">SystematicReviewEligibilityCriteria</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact (type: cite-as; citation: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href="https://fevir.net/resources/Group/179619">https://fevir.net/resources/Group/179619</a></p><p><b>identifier</b>: FEvIR Object Identifier/179619</p><p><b>name</b>: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer</p><p><b>title</b>: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p><strong>Study selection criteria</strong>
Types of Studies.
Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.</p>
<p>Types of participants.
Patients aged ≥18 years with cytological or histological diagnosis of mHNPC.</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 SystematicReviewEligibilityCriteria}">SystematicReviewEligibilityCriteria</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Study Design</span></p><p><b>value</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01003}">randomized assignment</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Randomized controlled clinical trials (RCTs)</p>
</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Study Design</span></p><p><b>value</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:01011}">Parallel cohort design</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>parallel design</p>
</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Comparison</span></p><p><b>value</b>: GroupAssignment: ADT plus docetaxel vs. ADT alone</p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>compared the association of ADT and chemotherapy (docetaxel), versus ADT alone</p>
</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 397669002}">Age</span></p><p><b>value</b>: >=18 years<span style="background: LightGoldenRodYellow"> (Details: UCUM codea = 'a')</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.
Patients aged ≥18 years</p>
</div><p><b>method</b>: <span title="Codes:">applied to participants in the studies</span></p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:{http://snomed.info/sct 64572001}">Disease (disorder)</span></p><p><b>value</b>: <span title="Codes:">metastatic hormone-naive prostate cancer</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Types of participants.
Patients with cytological or histological diagnosis of mHNPC.</p>
</div><p><b>method</b>: <span title="Codes:">applied to participants in the studies</span>, <span title="Codes:">cytological or histological diagnosis</span></p></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<url value="https://fevir.net/resources/Group/179619"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179619"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<name
value="SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer"/>
<title
value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
<status value="active"/>
<publisher value="Computable Publishing LLC"/>
<contact>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</contact>
<description
value="**Study selection criteria**
Types of Studies.
Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.
Types of participants.
Patients aged ≥18 years with cytological or histological diagnosis of mHNPC."/>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="SystematicReviewEligibilityCriteria"/>
<display value="SystematicReviewEligibilityCriteria"/>
</coding>
</valueCodeableConcept>
</useContext>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<membership value="conceptual"/>
<combinationMethod value="all-of"/>
<characteristic>
<code>
<text value="Study Design"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/181513"/>
<code value="SEVCO:01003"/>
<display value="randomized assignment"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
<description value="Randomized controlled clinical trials (RCTs)"/>
</characteristic>
<characteristic>
<code>
<text value="Study Design"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/181513"/>
<code value="SEVCO:01011"/>
<display value="Parallel cohort design"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
<description value="parallel design"/>
</characteristic>
<characteristic>
<code>
<text value="Comparison"/>
</code>
<valueReference>
<type value="EvidenceVariable"/>
<display value="GroupAssignment: ADT plus docetaxel vs. ADT alone"/>
</valueReference>
<exclude value="false"/>
<description
value="compared the association of ADT and chemotherapy (docetaxel), versus ADT alone"/>
</characteristic>
<characteristic>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="397669002"/>
<display value="Age"/>
</coding>
</code>
<valueQuantity>
<value value="18"/>
<comparator value=">="/>
<unit value="years"/>
<system value="http://unitsofmeasure.org"/>
<code value="a"/>
</valueQuantity>
<exclude value="false"/>
<description value="Types of participants.
Patients aged ≥18 years"/>
<method>
<text value="applied to participants in the studies"/>
</method>
</characteristic>
<characteristic>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="64572001"/>
<display value="Disease (disorder)"/>
</coding>
</code>
<valueCodeableConcept>
<text value="metastatic hormone-naive prostate cancer"/>
</valueCodeableConcept>
<exclude value="false"/>
<description
value="Types of participants.
Patients with cytological or histological diagnosis of mHNPC."/>
<method>
<text value="applied to participants in the studies"/>
</method>
<method>
<text value="cytological or histological diagnosis"/>
</method>
</characteristic>
</Group>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change